

Supplementary material for Patel et al., “Pharmacokinetic evaluation of differential drug release formulations of Rabeprazole in dogs”, *Drug Development and Industrial Pharmacy*, 2019.

Supplemental Table S1: Individual animal pharmacokinetic parameters of rabeprazole following 20 mg oral administration of rabeprazole sodium test drug product and reference product formulations in beagle dog.

	Test product 1 ^a (F011D)	Test product 2 (F011E)	Reference product (Acephex)
Dose (mg/dog)	20	20	20
T _{max} (h)	3, 4	1, 3, 3, 4.5	1, 2, 3, 3.5
C _{max} (ng/mL)	1771, 1546	225, 686, 660, 851	1621, 4360, 1505, 1073
AUC _{last} (ng*h/mL)	1633, 2166	441, 1288, 1955, 1171	1494, 5102, 1821, 2218
AUC _{inf} (ng*h/mL)	1641, 2168	457, 1522, 1959, 1175	1496, 5102, 1824, 2219
T _{1/2} (h)	9.6, 1.7	5.8, 25, 1.6, 1.7	1.2, 0.4, 1.1, 0.5
MRT (h)	4.4, 3.4	4.6, 3.0, 2.4, 3.1	3.5, 2.2, 3.3, 1.6
Relative bioavailability (%F)	62, 82	17, 44, 57, 74	100

^a Two animal showed poor absorption, excluded for PK evaluation

Supplemental Table S2: Individual animal pharmacokinetic parameter of rabeprazole sulfide following 20 mg oral administration of rabeprazole sodium test drug product and reference product formulations in beagle dog.

	Test product 1 ^a (F011D)	Test product 2 (F011E)	Reference product (Acephex)
Dose (mg/dog)	20	20	20
T _{max} (h)	3, 4.5	2, 3, 3, 4.5	2, 2, 3, 3.5
C _{max} (ng/mL)	34, 39	20, 29, 30, 42	63, 110, 61, 57
AUC _{last} (ng*h/mL)	74, 96	47, 73, 126, 74	86, 171, 156, 117
AUC _{inf} (ng*h/mL)	77, 99	52, 95, 130, 76	89, 173, 158, 119
T _{1/2} (h)	2.1, 2.2	4.5, 10.4, 2.5, 2.1	2.7, 2.1, 1.7, 1.5
MRT (h)	5.5, 4.5	5.3, 4.0, 4.0, 3.6	4.4, 2.7, 4.6, 2.2
% parent exposure	4.6, 4.7	6.2, 6.5, 6.6, 11.4	3.4, 5.3, 5.9, 8.7

^a Two animal showed poor absorption, excluded for PK evaluation